<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:identifier>https://scholia.toolforge.org/work/Q28552446</dc:identifier>
  <dc:identifier>http://www.wikidata.org/entity/Q28552446</dc:identifier>
  <dc:identifier>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881901</dc:identifier>
  <dc:identifier>doi:10.1371/JOURNAL.PONE.0154816</dc:identifier>
  <dc:title>Molecular Analysis of Rising Fluoroquinolone Resistance in Belgian Non-Invasive Streptococcus pneumoniae Isolates (1995-2014)</dc:title>
  <dc:creator>Ceyssens, Pieter-Jan</dc:creator>
  <dc:creator>Van Bambeke, Françoise</dc:creator>
  <dc:creator>Mattheus, Wesley</dc:creator>
  <dc:creator>Bertrand, Sophie</dc:creator>
  <dc:creator>Fux, Frédéric</dc:creator>
  <dc:creator>Van Bossuyt, Eddie</dc:creator>
  <dc:creator>Damée, Sabrina</dc:creator>
  <dc:creator>Nyssen, Henry-Jean</dc:creator>
  <dc:creator>Verhaegen, Jan</dc:creator>
  <dc:creator>Tulkens, Paul M</dc:creator>
  <dc:creator>Vanhoof, Raymond</dc:creator>
  <dc:type>journal article</dc:type>
  <dc:date>2016</dc:date>
  <dc:language>en</dc:language>
  <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
  <dc:subject>Streptococcus pneumoniae</dc:subject>
  <dc:subject>invasive species</dc:subject>
  <dc:publisher>Public Library of Science (PLoS)</dc:publisher>
  <dc:description>We present the results of a longitudinal surveillance study (1995-2014) on fluoroquinolone resistance (FQ-R) among Belgian non-invasive Streptococcus pneumoniae isolates (n = 5,602). For many years, the switch to respiratory fluoroquinolones for the treatment of (a)typical pneumonia had no impact on FQ-R levels. However, since 2011 we observed a significant decrease in susceptibility towards ciprofloxacin, ofloxacin and levofloxacin with peaks of 9.0%, 6.6% and 3.1% resistant isolates, respectively. Resistance to moxifloxacin arised sporadically, and remained </dc:description>
  <dc:coverage>n/a</dc:coverage>
</oai_dc:dc>